Literature DB >> 24395772

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics.

Niels Peter H Knudsen1, Sara Nørskov-Lauritsen, Gregory M Dolganov, Gary K Schoolnik, Thomas Lindenstrøm, Peter Andersen, Else Marie Agger, Claus Aagaard.   

Abstract

A central goal in vaccine research is the identification of relevant antigens. The Mycobacterium tuberculosis chromosome encodes 23 early secretory antigenic target (ESAT-6) family members that mostly are localized as gene pairs. In proximity to five of the gene pairs are ESX secretion systems involved in the secretion of the ESAT-6 family proteins. Here, we performed a detailed and systematic investigation of the vaccine potential of five possible Esx dimer substrates, one for each of the five ESX systems. On the basis of gene transcription during infection, immunogenicity, and protective capacity in a mouse aerosol challenge model, we identified the ESX dimer substrates EsxD-EsxC, ExsG-EsxH, and ExsW-EsxV as the most promising vaccine candidates and combined them in a fusion protein, H65. Vaccination with H65 gave protection at the level of bacillus Calmette-Guérin, and the fusion protein exhibited high predicted population coverage in high endemic regions. H65 thus constitutes a promising vaccine candidate devoid of antigen 85 and fully compatible with current ESAT-6 and culture filtrate protein 10-based diagnostics.

Entities:  

Keywords:  T-cell immunology; gene expression; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24395772      PMCID: PMC3903227          DOI: 10.1073/pnas.1314973111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle.

Authors:  J M Pollock; P Andersen
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 2.  Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Authors:  Mario Raviglione; Ben Marais; Katherine Floyd; Knut Lönnroth; Haileyesus Getahun; Giovanni B Migliori; Anthony D Harries; Paul Nunn; Christian Lienhardt; Steve Graham; Jeremiah Chakaya; Karin Weyer; Stewart Cole; Stefan H E Kaufmann; Alimuddin Zumla
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

3.  The World Health Organization and public health research and practice in tuberculosis in India.

Authors:  Debabar Banerji
Journal:  Int J Health Serv       Date:  2012       Impact factor: 1.663

4.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

5.  Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved.

Authors:  Iñaki Comas; Jaidip Chakravartti; Peter M Small; James Galagan; Stefan Niemann; Kristin Kremer; Joel D Ernst; Sebastien Gagneux
Journal:  Nat Genet       Date:  2010-05-23       Impact factor: 38.330

6.  Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.

Authors:  Thomas Lindenstrøm; Else Marie Agger; Karen S Korsholm; Patricia A Darrah; Claus Aagaard; Robert A Seder; Ida Rosenkrands; Peter Andersen
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

7.  Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice.

Authors:  P Andersen; A B Andersen; A L Sørensen; S Nagai
Journal:  J Immunol       Date:  1995-04-01       Impact factor: 5.422

8.  Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig.

Authors:  Randall J Basaraba; Helle Bielefeldt-Ohmann; Ellie K Eschelbach; Claire Reisenhauer; Airn E Tolnay; Lauren C Taraba; Crystal A Shanley; Erin A Smith; Cathy L Bedwell; Elizabeth A Chlipala; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2007-10-17       Impact factor: 3.131

9.  Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig.

Authors:  M J Elhay; T Oettinger; P Andersen
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

10.  Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines.

Authors:  Hannah Priyadarshini Gideon; Katalin Andrea Wilkinson; Tige R Rustad; Tolu Oni; Heinner Guio; Robert Andrew Kozak; David R Sherman; Graeme Meintjes; Marcel A Behr; Hans Martin Vordermeier; Douglas Brownlee Young; Robert John Wilkinson
Journal:  PLoS Pathog       Date:  2010-12-23       Impact factor: 6.823

View more
  22 in total

1.  Protein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infection.

Authors:  Truc Hoang; Else Marie Agger; Joseph P Cassidy; Jan P Christensen; Peter Andersen
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

2.  Immunization with Mycobacterium tuberculosis-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in Mice.

Authors:  Claus Aagaard; Niels Peter Hell Knudsen; Iben Sohn; Angelo A Izzo; Hongmin Kim; Emma Holsey Kristiansen; Thomas Lindenstrøm; Else Marie Agger; Michael Rasmussen; Sung Jae Shin; Ida Rosenkrands; Peter Andersen; Rasmus Mortensen
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

3.  High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Authors:  Thomas Lindenstrøm; Claus Aagaard; Dennis Christensen; Else M Agger; Peter Andersen
Journal:  Eur J Immunol       Date:  2014-03-27       Impact factor: 5.532

4.  Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis.

Authors:  Sirwan Zare; Mona Kabiri; Yousef Amini; Adel Najafi; Fatemeh Mohammadpour; Seyed Hasan Ayati; Amin Reza Nikpoor; Mohsen Tafaghodi
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

5.  Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.

Authors:  Mark T Orr; Gregory C Ireton; Elyse A Beebe; Po-Wei D Huang; Valerie A Reese; David Argilla; Rhea N Coler; Steven G Reed
Journal:  J Immunol       Date:  2014-08-01       Impact factor: 5.422

Review 6.  Novel vaccination strategies against tuberculosis.

Authors:  Peter Andersen; Stefan H E Kaufmann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 7.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

8.  Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice.

Authors:  Hongxia Niu; Jinxiu Peng; Chunxiang Bai; Xun Liu; Lina Hu; Yanping Luo; Bingxiang Wang; Ying Zhang; Jianzhu Chen; Hongjuan Yu; Qiaoyang Xian; Bingdong Zhu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 9.  The Zebrafish Breathes New Life into the Study of Tuberculosis.

Authors:  Henna Myllymäki; Carina A Bäuerlein; Mika Rämet
Journal:  Front Immunol       Date:  2016-05-19       Impact factor: 7.561

10.  Heterologous Expression, Purification, and Characterization of the HspX, Ppe44, and EsxV Proteins of Mycobacterium tuberculosis.

Authors:  Yousef Amini; Mohsen Tafaghodi; Saeid Amel Jamehdar; Zahra Meshkat; Bagher Moradi; Mojtaba Sankian
Journal:  Rep Biochem Mol Biol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.